Latest Funding News

Vital Metals Limited has released a comprehensive Scoping Study for its Tardiff Rare Earths deposit in Canada, revealing strong economic potential with an 11-year mine life and significant neodymium-praseodymium resources.

Syrah Resources has resumed production at its Balama graphite mine after a year-long halt and is advancing sales at its US Vidalia anode material facility, supported by new US tariffs on Chinese imports and a $70 million equity raise.

White Cliff Minerals confirms significant high-grade copper and silver mineralisation at its Danvers prospect, raising A$14.4 million to fund expanded exploration. The company also announces a strategic board appointment as it advances its Rae Copper and Great Bear projects.

Syrah Resources has launched a fully underwritten A$70 million equity raising to support its Balama graphite operations and Vidalia Active Anode Material facility, alongside securing a two-year forbearance on its US Department of Energy loan. The company advances commercial qualification of Vidalia AAM amid strong demand and US tariff support.

Syrah Resources has launched a A$70 million equity raising and secured a two-year forbearance on its US Department of Energy loan, bolstering its cash position and operational flexibility amid ongoing challenges.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Transurban Group reveals modest participation in its latest Distribution Reinvestment Plan, with new securities priced at $13.4692 ahead of the August payment date.

Arizona Lithium has secured regulatory approval for Phase 1 production at its Prairie Lithium Project in Saskatchewan and raised $4.25 million through an oversubscribed share purchase plan, marking key milestones toward commercial lithium extraction.

Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.

Sequoia Financial Group has responded to an ASX price query, denying any undisclosed material information behind recent trading fluctuations and reaffirming compliance with listing rules amid ongoing ASIC investigations.

Identitii Limited has refinanced a $0.8 million loan with an interest-free facility from its largest shareholder, Beauvais Capital, reducing interest expenses and freeing up company assets.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.